
Tarlatamab Demonstrates Superior Intracranial and Systemic Efficacy in Relapsed Extensive-Stage Small Cell Lung Cancer: Results from the Phase 3 DeLLphi-304 Trial and Real-World Analyses
<a href="https://news.google.com/rss/articles/CBMitgJBVV95cUxOa1ZuU1JqOVZ4NDJWR0FnSjJLbWU5QW9HTXZCZzhaaEw5S08wMWxBUXpYT3EyVjljU1NEdS1xV3o4bUF1RXNQNVcyZTJjVzU5RjRQb0NKNDdGMXhBQ1I0UEhqRWNMMjh0N2dqbEFYcVBWS2V0eUs2VUQwUFE2UnVqRkZqX2wwRzFYRjhENU5MNmtrMUUwS25sVXhIZWRBa0VUZWZsQjJrYXhzbHFzQzlwLVhDMjdyVExuS014c1Y1RThsM0RBdlhGc1RqZy10R19yNENRVFQySmZiVE9GM3V2dkh6bnN2S3FGU1VYRWxJMmh4VmtJM1g3cFhsSHR5dEVMcnNLNE1vM1QwOTRBWGxGbDg0Y2liLXNDUkdmcWFwUGVPanN6aTE4eVlrVjZBalgyTTlMVkZn?oc=5" target="_blank">Tarlatamab Demonstrates Superior Intracranial and Systemic Efficacy in Relapsed Extensive-Stage Small Cell Lung Cancer: Results from the Phase 3 DeLLphi-304 Trial and Real-World Analyses</a>&nbsp;&nbsp;<font color="#6f6f6f">Onco'Zine</font>

